Minerva Neurosciences (NERV) Gains from Investment Securities (2013 - 2026)

Minerva Neurosciences has reported Gains from Investment Securities for 14 years, with the latest figure at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 26885.64% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (up 26885.64% YoY), and the FY2025 full-year result was $8.2 million, up 449.58% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $9.0 million, up from $8.2 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $9.0 million in Q1 2026, with the low at $20218.0 in Q1 2024.
• Historically, Gains from Investment Securities has averaged $1.6 million across 5 years, with a median of $228209.0 in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities tumbled 88.72% — and 2026, when it jumped 26885.64%.
• Minerva Neurosciences' Gains from Investment Securities stood at $202500.0 in 2022, then tumbled by 69.14% to $62500.0 in 2023, then surged by 2279.57% to $1.5 million in 2024, then surged by 449.58% to $8.2 million in 2025, then increased by 9.94% to $9.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $9.0 million (Q1 2026), $8.2 million (Q4 2025), and $30932.0 (Q3 2025), per Business Quant data.